TransCode Therapeutics entered into an Exclusive Licensing Agreement with Unleash Immuno Oncolytics, Inc. on March 2, 2026, acquiring a preclinical candidate program involving genetically-engineered adenoviruses to fight cancer. The agreement grants TransCode exclusive, perpetual, irrevocable, worldwide, fully-paid up, royalty-free, sublicensable rights and license to related technology, including drug candidates UIO-524, UIO-525, and UIO-526. As consideration, TransCode issued 1,136,364 shares of its newly designated Series C Non-Voting Convertible Preferred Stock to Unleash. These Series C Preferred Stock shares represent 6.8% of TransCode's common stock on a fully diluted basis, assuming conversion of all outstanding preferred stock. Tungsten Advisors, acting as financial advisor, received 77,841 shares of Series C Preferred Stock as compensation for services rendered. The Series C Preferred Stock is not convertible into common stock until TransCode's stockholders approve the conversion in accordance with Nasdaq listing rules, and is subject to a 4.99% beneficial ownership limitation for each holder, which can be adjusted or waived under certain conditions.